

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



---

# *Helicobacter pylori* Infection and Diabetes Mellitus

---

Saeda Haj, Michal Raviv and Khitam Muhsen

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/63826>

---

## Abstract

*Helicobacter pylori* colonizes the stomach and causes chronic gastritis, which most often remains asymptomatic. However, in a small proportion of infected persons, it causes peptic ulcers and gastric cancer. We reviewed recent evidence of the association between *H. pylori* infection and diabetes mellitus (DM). Numerous studies have shown a positive association between *H. pylori* infection and DM, however, findings are still conflicting. Such a link is biologically plausible, given the importance of the stomach in the homeostasis of systems outside the digestive tract; however, the mechanisms by which *H. pylori* might affect the risk of DM are not clear. Current knowledge indicates that *H. pylori* infection can affect the regulation of ghrelin and leptin, two hormones that play central roles in energy homeostasis in humans. Yet, methodological limitations are present in studies that addressed the relationships of *H. pylori* infection with DM and with possible risk factors for DM, including inadequate control of confounders. The important question of whether *H. pylori* eradication might be beneficial for glycemic control in diabetic patients is still unresolved. Future well-designed studies are needed to address these research questions, which are of clinical and great public health significance.

**Keywords:** *Helicobacter pylori*, diabetes mellitus, epidemiology

---

## 1. Introduction

*Helicobacter pylori* is a gram-negative bacterium that colonizes the stomach and causes persistent infection. The infection is typically acquired in the first few years of life [1–3]. The associated risk factors of *H. pylori* infection include living in crowded households, low socioeconomic conditions and infected family members [4–6]. The infection is common worldwide with highest prevalence rates reaching 80–90% in developing countries and underprivileged communities [7], while a much lower prevalence of 20–50% is recorded in developed countries [7].

*H. pylori* infection has two phases: an acute phase and a chronic course. Acute *H. pylori* infection is rarely diagnosed. Following establishment of the infection, chronic gastritis develops; however, most infected people remain asymptomatic and only 10–20% of them develop peptic disease during their lifetime [7]. *H. pylori* causes gastric and duodenal ulcers, and in rare occasions distal gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [7]. These diseases are the main indications to test and treat *H. pylori* infection [8], in addition to unexplained iron deficiency anemia (IDA) and idiopathic thrombocytopenic purpura [8]. Although *H. pylori* infection is acquired in childhood, peptic ulcer disease typically occurs in adulthood.

Following *H. pylori* colonization, rigorous local and systemic immune responses develop. However, these do not clear the infection but rather contribute to the damage of the gastric mucosa [7, 9, 10]. *H. pylori* simulates the innate immune response, as well as humoral and cell-mediated immune responses [9, 10]. The predominant human T cell response is the T-helper 1 mediated response, which is associated with releasing proinflammatory cytokines and activation of phagocytes [9, 10]. *H. pylori* also induces Th2 and T-regulatory (Tregs) responses [9, 10]. The importance of Treg response is in both controlling inflammation and promoting the persistence of the infection [9, 10].

*H. pylori*-associated gastric pathology develops over time in a progressive manner [11–13], and the damage to gastric mucosa can be observed even in asymptomatic persons [14]. Today it is clear that host (e.g., age, genetic susceptibility), agent (virulence antigens) and environment-related factors are important in the development of *H. pylori*-associated gastroduodenal diseases [9]. For example, host genetic polymorphisms that lead to increased release of proinflammatory cytokines are associated with increased gastric cancer risk [9]. Pathogenesis is dependent on a Th1-acquired immune response and on hormonal changes including hypergastrinemia [9]. Regarding pathogen virulence factors, most *H. pylori* strains carry the *cag* pathogenicity island that encodes for a type IV secretory apparatus, which allows translocation of cytotoxin-associated gene A (CagA) protein into the host cell. This, together with the vacuolating cytotoxin (VacA), plays a major role in the pathogenesis of gastroduodenal diseases [7, 9, 15–17]. Novel *H. pylori* antigens have been identified recently [18], some of which were found to be associated with atrophic gastritis and gastric cancer risk such as GroEL [18], Helicobacter cysteine-rich protein (HcpC) [19], outer membrane protein (Omp) and others [20, 21].

Several studies have shown associations between *H. pylori* infection and various extragastric diseases [22]. *H. pylori* infection was positively linked with adulthood chronic diseases such as cardiovascular disease [23–25], dementia [26–28], insulin resistance and diabetes mellitus (DM) [22, 29, 30]. The mechanisms of such associations are not fully understood, and it is not clear whether such associations are causal or not. This chapter will focus on the association between *H. pylori* infection and DM.

## **2. *H. pylori* infection, changes in gastric physiology and metabolic hemostasis**

Although the role of *H. pylori* infection in the pathogenesis of gastroduodenal diseases [7, 9, 17, 31] is well established, its impeding effects on metabolic homeostasis and DM are not clear.

The stomach plays a major role in the homeostasis of systems outside the digestive tract. Therefore, the link between *H. pylori*-chronic gastritis and metabolic homeostasis and DM seems biologically plausible.

*H. pylori*-induced inflammation and its severity affect gastric physiology. For example, *H. pylori* leads to hormonal changes in the stomach, such as reduced production of somatostatin and hypergastrinemia [9]. *H. pylori*-gastritis also alters the secretion of gastric acid [32, 33]; increased secretion of gastric acid is associated with antral-predominant phenotype and increased risk of duodenal ulcers [9, 10]. *H. pylori* infection can reduce gastric acid production, and this is typically associated with corpus-predominant gastritis and increased likelihood of gastric ulcer and gastric adenocarcinoma [9, 10]. Moreover, *H. pylori* infection is associated with reduced gastric ascorbic acid levels [34]. *H. pylori* affects the levels of pepsinogen (PG) I and PGII; proenzymes of the digestive enzyme pepsin. PGI is secreted from cells in the corpus and PGII is also secreted from cells in the antrum and duodenum [35, 36]. About 1% of PGs can be found in the serum. Serum PGI and PGII are increased in *H. pylori* infected vs. uninfected individuals, and higher levels are found in more severe gastritis. As the severity of gastritis progresses and corpus atrophic lesions appear, the PGI level decreases, while the PGII level remains stable; the result is a decrease in the PGI:PGII ratio [37, 38]. These markers have clinical significance, and they predict various gastric pathologies [16, 37–40].

In addition, *H. pylori* infection can affect the regulation of ghrelin and leptin [41–47], two hormones that play central roles in energy homeostasis [48]. Ghrelin reduces energy expenditure and promotes weight gain [48–50], while leptin decreases appetite and increases energy expenditure [48]. Both hormones are secreted by the epithelial cells in the stomach [48, 51]. The relationship between *H. pylori* and these hormones appears to be complex. While several studies reported no association between *H. pylori* infection and circulating leptin [43, 45, 46, 52–54] and ghrelin levels [45, 52, 54], others found lower levels of one or the two hormones in *H. pylori* infected vs. uninfected individuals [41, 42, 44]. There also appears to be differences in gastric mucosa levels of these hormones, according to *H. pylori* infection [41, 42, 47, 52–54]. Moreover, *H. pylori* eradication seems to affect these hormones as well [41, 43, 45, 47, 52] (Table 1).

Study	Exposure	Ghrelin		Leptin	
		Circulating levels	Gastric mucosa levels	Circulating levels	Gastric mucosa levels
	<i>H. pylori</i> infection	↓	↓	ND	ND
Isomoto et al. [44]	<i>H. pylori</i> eradication	NS	NS	ND	ND
Chuang et al. [46]	<i>H. pylori</i> infection	Males: ↓ Females: NS	ND	NS	ND
Jun et al. [52]	<i>H. pylori</i> infection	NS	NS	NS	↑
Nishi et al. [53]	<i>H. pylori</i> infection	ND	ND	NS	↑

Study	Exposure	Ghrelin		Leptin	
		Circulating levels	Gastric mucosa levels	Circulating levels	Gastric mucosa levels
	<i>H. pylori</i> eradication	ND	ND	NS	
	<i>H. pylori</i> infection	NS	ND	NS	ND
Francois et al. [45]	<i>H. pylori</i> eradication	Pre-meal: NS Post meal: ↑	ND	↑	ND
	<i>H. pylori</i> infection	ND	ND		↑
Azuma et al. [47]	<i>H. pylori</i> eradication	ND	ND	NS	↓
Jang et al. [54]	<i>H. pylori</i> eradication	NS	↑	NS	ND
Roper et al. [41]	<i>H. pylori</i> infection	NS	Fundic: NS Antral: NS Gastric juice: ↑	↓	Fundic: NS Antral: ↓
Breidert et al. [43]	<i>H. pylori</i> infection	ND	ND	NS	Antrum: NS Corpus: ↑

NS, no significant difference; ND, not determined; ↑ increase; ↓ decrease.

**Table 1.** Selected studies that addressed associations of *H. pylori* infection and *H. pylori* eradication with ghrelin and leptin levels

Altogether, these studies suggest that *H. pylori* can alter gastric physiology, which can in turn affect metabolic homeostasis and the risk of DM.

### 3. *H. pylori* infection and diabetes mellitus

DM refers to a group of metabolic disorders that manifest with hyperglycemia. DM is classified based on the pathogenic course that results in hyperglycemia, with two broad categories designated as type 1 DM (T1DM) and type 2 DM (T2DM). T1DM is the result of interaction among genetic, environmental and immunological factors that eventually leads to destruction of beta cells in the pancreas and complete or near-complete insulin deficiency. T2DM consists of various disorders with variable levels of insulin resistance, impaired insulin secretion and increased glucose production. T1DM usually occurs in childhood and adolescence, and comprises 5–10% of all DM cases [55]. T2DM typically develops in adulthood and is responsible for the majority (90–95%) of DM cases [55].

DM is a major public health problem [56–60], causing an enormous burden to patients and their families, as well as to health care systems. The prevalence of T2DM is increasing globally

[56–60] due to increases in life expectancy and obesity [56, 58]. It is estimated that 240 million people have T2DM, and that in 2025 about 380 million will have the disease, while 418 million will have impaired glucose tolerance (IGT) [56]. The burden of DM is amplified given its significant macro and microvascular complications (such as cardiovascular disease, kidney disease), in addition to peripheral neuropathy [55].

There are well-established risk factors for T2DM [61–67], including sociodemographic factors [64, 68, 69], lifestyle factors (e.g., obesity, physical inactivity, poor diet [61–67]) and high glucose levels reflecting IGT [65, 66]. Changes in diet (i.e., higher consumption of whole grain products and exchanging unsaturated fat for saturated fat), and in particular physical activity and avoidance of obesity, can prevent T2DM through changes in body fat and other mechanisms [61, 67, 70–72]. These may reduce the incidence of DM by 28–59% [72]. Such interventions are also important for better control of diabetes [70, 73]. Current evidence suggests that there must be additional factors besides lifestyle that contribute to the occurrence of DM.

In addition to the association mentioned above, between *H. pylori* infection and ghrelin and leptin [41, 45, 74–80], associations have been reported of *H. pylori* infection with glycosylated hemoglobin levels (Hb1Ac) [81], as well as with disturbances in metabolic homeostasis including insulin resistance; the latter according to a recent literature review and a systematic review [22, 82]. These findings support the postulation that *H. pylori* infection may be involved in the etiology of the emerging pandemic of obesity and DM, and in diabetes-related complications.

Associations of *H. pylori* infection with DM incidence [30, 83, 85] have been reported. Recent meta-analyses showed a significant 1.7 to 2-fold higher prevalence of *H. pylori* infection in persons with T2DM vs. non-diabetic individuals [84, 85]. In some of the studies that reported a positive association between *H. pylori* infection and DM [30, 86–88], the association became non-statistically significant after adjustment for potential confounders such as age and socioeconomic status [87, 88]. Other studies reported no significant association between *H. pylori* and DM [89–92], or a significant association only in persons with BMI>25 [81] (Table 2). Several studies did not control adequately for socioeconomic status and for traditional risk factors of DM, such as obesity and physical inactivity. Furthermore, most of the evidence is based on small-scale hospital-based case-control studies, in which the source population, selection of control population and representativeness of the sample were not fully described. For these reasons, inference and generalizability of findings from such studies should be done with caution. On the other hand, recent well-designed studies show convincing evidence of the potential involvement of *H. pylori* infection in the occurrence of DM, and possibly in IGT. A large population-based follow-up investigation of elderly persons has demonstrated a significant two-fold increased risk of DM in *H. pylori* infected vs. uninfected persons, even after controlling for possible confounders, while such an association was not observed for other pathogens [30]. A large well-designed and thoroughly analyzed survey that utilized nationwide data ( $N \sim 13,000$ ) from the United States indicated no significant association between *H. pylori* infection and self-reported diabetes. However, among individuals with BMI>25 kg/m<sup>2</sup> who were assessed in the 1999–2000 National Health & Nutrition Examination Survey (NHANES), DM was more prevalent among those who were *H. pylori* seropositive than those

who were *H. pylori*-seronegative[81] (Table 2). Moreover, that study showed that *H. pylori* infected persons, especially those infected with CagA strains, had significantly elevated mean HbA1c levels compared with those who were *H. pylori* seronegative [81].

Study	Study population	Study design	<i>Hp</i> detection	Outcome	Findings	Adjusting for confounders
Jeon et al. [30] California	N=782 diabetes free individuals at baseline Age >60 years	Prospective cohort	Serum IgG by ELISA	DM	Adjusted HR 2.69 (95% CI: 1.10–6.60)	Sex, education, smoking, cholesterol, DBP, HSV-1
Hsieh et al. [86] Taiwan	N=903 <i>Hp</i> infected patients aged 57.16±11.64 years N=1167 uninfected patients aged 56.57±13.34 years	Cross-sectional	Gastric biopsy: culture, histology and rapid urease test	T2DM	OR 1.67 (95% CI: 1.19–2.35)	
Chen and Blaser [81] USA	Data from NHANES III N=7417 age ≥18 years NHANES 1999–2000 N=6072 age ≥3 years	Cross-sectional	Serum IgG by ELISA	DM	NHANES 1999–2000: Adjusted OR: 1.30 (95% CI: 0.94–1.80) BMI>25 OR (1.43; 95% CI: 1.00–2.03) NHANES III: Adjusted OR: 0.99 (95% CI: 0.80–1.23)	Age, sex, race, BMI, smoking, education
El-Eshmawy et al. [111] Egypt	N=162 T1DM patients aged 19.35±2.6 years N=80 healthy subjects aged 19.76±2.76 years	Case-control	Serum IgG and IgA by ELISA	T1DM	OR 3.67 (95% CI: 2.07–6.55)	Matching by age, sex, SES
Longo-Mbenza et al. [91] Democratic Republic of the Congo	N=128 patients with <i>Hp</i> infection aged 53.4±12.9 years N=77 uninfected patients aged 52.5±16.6 years	Prospective cohort Follow-up 9.6±0.8 years	Serum IgG by ELISA	DM	OR: 0.97 (95% CI: 0.35–2.86)	
Xia et al. [89] Australia	N=49 T1DM and N=380 T2DM (aged 60.7±13.3 years) N=170 non-diabetic controls aged 60.4± 11.3 years	Case-control	Serum IgG by ELISA	T1DM T2DM	Overall 0.94 (95% CI: 0.65–1.39) T2DM: OR: 1.03 (95% CI: 0.71–1.52) T1DM: OR: 0.40 (95% CI: 0.15–0.94)	

Study	Study population	Study design	<i>Hp</i> detection	Outcome	Findings	Adjusting for confounders
Demir et al. [90] Turkey	N=141 T2DM patients aged 52±8.2 years N=142 non-diabetic subjects aged 51±9.3 years	Case-control	Gastric biopsy: rapid urease test and histology	T2DM	OR: 1.15 (95% CI: 0.71–1.85)	
Colombo et al. [112] Italy	N=138 T1DM patients aged 12.0±3.4 years N=138 controls aged 12.2±2.0 years	Case-control	Serum IgG and IgA by ELISA	T1DM	OR: 0.87 (95% CI: 0.52–1.46)	Matching by age
Cenerelli et al. [92] Italy	N=30 T2DM patients aged 55.7±9.7 years N=43 controls aged 51.2±11.3 years	Case-control	UBT	T2DM	OR: 1.06 (95% CI: 0.41–2.76)	
Dore et al. [87]	N=145 T1DM and N=240 T2DM N=506 controls (ages 12–75 years)	Case-control	Serum IgG by ELISA	T1DM T2DM	T1DM: 0.59 (95%CI: 0.40–0.87) T2DM: 2.08 (95%CI: 1.52–2.85)	In stratified analysis by age group, SES, the differences were not significant
Lutsey et al. [88]	N= 1000 ages 45–84 years	Cross-sectional	Serum IgG by ELISA	DM	Crude OR: 1.65 (95%CI: 1.16–2.34) Adjusted OR: 1.12 (0.78–1.62)	Age, sex, rate, education and site

BMI, body mass index; CI, confidence intervals; DM, diabetes mellitus; DBP, diastolic blood pressure; ELISA, enzyme-linked immunosorbent assay; *Hp*, *Helicobacter pylori*; HR, hazard ratio; HSV-1, *Herpes simplex virus 1*; IgA, immunoglobulin A; IgG, immunoglobulin G; NHANES, National Health & Nutrition Examination Survey; OR, odd ratio; SES, socioeconomic status; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UBT, urea breath test.

**Table 2.** Selected epidemiological studies that examined an association between *H. pylori* infection and diabetes mellitus

#### 4. *H. pylori* infection and glycemic control among diabetic patients

Given the observed associations between *H. pylori* infection and various metabolic and glycemic measures, the question arises of whether *H. pylori* infection and/or *H. pylori* eradication can affect glycemic control in diabetic patients. If indeed *H. pylori* infection plays a role in glycemic control, *H. pylori* eradication might be beneficial to diabetic patients. A recent meta-analysis that included 14 observational studies involving 1781 diabetic patients (both T1DM and T2DM) showed no significant difference in mean HbA1c values among *H. pylori* infected individuals compared with those uninfected; mean difference 0.19% (95% CI: -0.18 to 0.46),



(Pv=0.16) [93]. In contrast, another meta-analysis involving 11 studies and 513 patients reported significantly higher HbA1c values among *H. pylori*-infected diabetic persons than among uninfected ones: weighted mean difference 0.43 (95% CI: 0.07–0.79), (Pv=0.02) [94]. The discrepancy in results between the two meta-analyses can be explained by differences in their criteria of study selection, which determined the number and quality of the studies analyzed.

Study	Study population	<i>H. pylori</i> infection	Intervention	Outcome	Findings	Adjusting for confounders
<b>T2DM</b>						
Zojaji et al. [95]	<i>Hp</i> positive T2DM patients (N=85). Mean age 52.3 ±4.7 yrs, 31.8% males	Serum IgG antibodies by ELISA	OCA for 14 d.	HbA1c, FPG	Mean HbA1c levels before successful treatment were 8.7±1.1% and 3 m. after treatment were 8.3±0.9% (P<0.001)	None
Iran					FPG before successful treatment were 145±22 mg/dl and 3 m. after treatment were 133±18 mg/dl (NS)	
					No significant change in HbA1c was found before and after therapy among patients with no successful <i>Hp</i> eradication	

Vafaeimanes et al. [97] Iran	<p><i>N</i>=191 <i>Hp</i> positive patients aged 55.6±9.8 yrs, 53.9% males</p> <p>T2DM patients non-insulin users (<i>N</i>=93) and non-diabetic patients (<i>N</i>=98) with upper GI symptoms</p>	Gastroscopy and biopsy: histology	<p>Quadruple therapy for 14 d. (<i>N</i>= 96; 47 diabetic and 49 non-diabetic patients): OMAB</p> <p>Triple therapy for 14 d. (<i>N</i>=95; 46 diabetic and 49 non-diabetic patients): OCA</p>	HbA1c, FPG	<p><i>Hp</i> eradication was successful in 63% of T2DM patients vs. 87.7% in non-diabetic patients who received OCA therapy (<i>P</i>=0.017) and 38.2 vs. 55.1%, respectively (<i>P</i>&lt; 0.001) in those who received OMAB</p> <p>Decrease in HbA1c level 3 and 6 m after treatment was 0.23±0.91% vs. 0.25±0.85% and 0.19±0.85% vs. 0.20±0.91% in T2DM patients who had successful <i>Hp</i> eradication vs. no eradication, respectively (NS)</p>	Age and sex-matching between diabetic and non-diabetic patients
---------------------------------	--	-----------------------------------	--	------------	--	---

Wada et al. [96] Japan	T2DM patients (N=72) who received <i>Hp</i> eradication therapy. Mean age 63.7 ±1.1 yrs, 76.4% males	Gastric biopsy	AC plus lansoprazole (N=65) or Omeprazole (N=2), or rabeprazole (N=5) for 7 d.	HbA1c	Decrease in FPG level 3 and 6 m. after treatment was 10.9±12.1 mg/dl vs. 9.5±14.3 mg/dl and 8.9±16.8 mg/dl vs. 9.4±15.6 mg/dl in T2DM patients who had successful <i>Hp</i> eradication vs. no eradication, respectively (NS)  HbA1c levels did not show significant change after therapy 6.9% ±0.1% 3 m. before to 7.0 ±0.1% 3 m. after (P=0.3), 7.0 ±0.1% after 6 m. (P=0.3)
Akanuma et al. [98] Japan	T2DM <i>Hp</i> infected patients (N=174) aged 65±7 yrs, 83.9% males without GI complications who had successful <i>Hp</i> eradication therapy	Gastroscopy biopsy:  Culture, histology, rapid urease test serum IgG antibodies  UBT	First-line treatment: LR or OCA (N=119)  Patients with penicillin allergy: LCM (N=3)  Quadruple therapy: LACM (N=24)  Second-line therapy: lansoprazole or	HbA1c	Overall, no significant changes in mean HbA1c values were observed 1 year before and after <i>Hp</i> eradication (P=0.07)  Among patients with uncontrolled diabetes (N=76), HbA1c levels decreased

T1DM	Candelli et al. [99] Italy	T1DM patients aged 13.6±4.6 yrs, 51.7% males infected with <i>Hp</i>	UBT	RAM (N=28) Regimens were given for 7 d.	ACR for 7 d.	HbA1c	<p>significantly between baseline and post <i>Hp</i> eradication (<math>P=0.08</math>): 8.22±0.92% at baseline 8.08 ±1.1% 3 m. 7.95 ±1.2% 6 m. 8.06 ±1.1% 9 m. 7.99 ±0.99% 12 m.</p> <p>Among patients with controlled diabetes (N=98), HbA1c levels increased between baseline and post-<i>Hp</i> eradication (<math>P=0.41</math>): 6.77±0.4% at baseline 6.88 ±0.6% 3 m. 6.97 ±0.6% 6 m. 7.00 ±0.6% 9 m. 7.01 ±0.6% 12 m.</p> <p>No difference in HbA1c level was observed between <i>Hp</i> infected and</p>	Sex, age, family income, BMI

<p>Begue et al. [100] Louisiana</p>	<p>(<i>N</i>=29) and uninfected T1DM patients aged 13.1±4.2 yrs, 51.7% males (<i>N</i>=29)</p> <p>T1DM patients aged 7–17 yrs with asymptomatic <i>Hp</i> infection (<i>N</i>=8) and uninfected T1DM patients aged 6–18 (<i>N</i>=16)</p>	<p>Serum IgG antibodies, UBT</p>	<p>OCM for 14 d.</p>	<p>HbA1c</p>	<p>uninfected patients.</p> <p>8.25±1.06% vs. 8.4±1.7% (NS)</p> <p>No difference in HbA1c level was observed in patients before and 6 m. after eradication 8.2±1% vs. 8.3±1% (NS) nor between <i>Hp</i> infected patients and uninfected ones 6 m after the evaluation of <i>Hp</i> status</p> <p>HbA1c values were higher among T1DM <i>Hp</i> infected patients than T1DM uninfected patients at the beginning of the study (median, 13.6% and 11.0%, respectively; <i>P</i>=0.07)</p> <p>After treatment, T1DM <i>Hp</i>-infected patients had a steady decrease in HbA1c level (slope = -0.10), whereas uninfected T1DM patients had a slightly increasing trend (slope= +0.03) (<i>P</i>= 0.05)</p>	<p>Age, race, BMI, diabetes duration and compliance with clinical appointments</p>
---	---	----------------------------------	----------------------	--------------	--	--

Table 3. Helicobacter pylori eradication and glycaemic control in diabetic patients

de Luis et al. [101] Spain	<i>Hp</i> -infected T1DM patients ( <i>N</i> =13) aged 44.9±15.5 yrs, 30.77% males	Serum IgG antibodies, UBT, gastric biopsy	First-line therapy OCA for 10 d.  In persistent infection: retreatment adding bismuth for 10 d.	HbA1c	After 2 yrs, HbA1c values were similar in <i>Hp</i> infected and uninfected patients (median: 11.7 and 11.4%, respectively; <i>P</i> = 0.69)  HbA1c levels before and 6 m after <i>Hp</i> eradication were 7.±1.7% vs. 7.5±0.6% in patients free of gastritis ( <i>N</i> =9) and 7.1±1.1% vs. 6.8±1.4% in patients with gastritis ( <i>N</i> =4). All NS
-------------------------------	--	---	---	-------	--

A, amoxicillin; B, bismuth; BMI, body mass index; C, clarithromycin; d, days; ELISA, enzyme linked immunosorbent assay; FPG, fasting plasma glucose; GI, gastrointestinal; HbA1c, glycosylated hemoglobin; *Hp*, *Helicobacter pylori*; IgG, immunoglobulin G; L, lansoprazole; m, months; NS, not significant; O, omeprazole; OCA, omeprazole 20 mg and clarithromycin 500 mg and amoxicillin 1 g each twice a day; OMAB, omeprazole 20 mg and metronidazole 500 mg and amoxicillin 1 g and bismuth subcitrate 240 mg, each twice a day; PU, peptic ulcer; R, rabeprazole; SES, socioeconomic status; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UBT, urea breath test; yrs, years.

The question of whether *H. pylori* eradication can improve glycemic control was assessed in a limited number of observational studies, most of them were small scale [95–101] (Table 3). Findings from these studies were conflicting, ranging from no difference, to small non-significant or borderline improvements from baseline to up to 2-years after eradication [95–101] and to a significant decrease from baseline, in HbA1c at 3 months after *H. pylori* eradication [95]. A pooled analysis of two studies that compared mean differences in HbA1c between diabetic individuals who had undergone successful *H. pylori* eradication and those whose *H. pylori* eradication therapy had failed, showed no significant difference between the groups [94]. The optimal study design to examine the effect of *H. pylori* eradication therapy on glycemic control is a randomized controlled trial with intention-to-treat analysis, in which diabetic patients are assigned to either an *H. pylori* eradication group or a placebo control group. However, to-date such trials are lacking, and the current evidence is based on observational studies, which are evidently prone to biases and confounders. Therefore, the question of whether *H. pylori* infection affects glycemic control in diabetic patients remains unresolved.

## 5. *H. pylori* infection and metabolic syndrome

Metabolic syndrome is a cluster of metabolic risk factors that are associated with increased risk for atherosclerotic cardiovascular disease, T2DM and their complications. These factors include atherogenic dyslipidemia (elevated triglycerides and apolipoprotein B, increases small low-density lipoproteins [LDL], and low concentration of high-density lipoproteins [HDL]), elevated blood pressure and elevated fasting glucose levels known as impaired fasting glucose (IFG) or prediabetes [102, 103], which lead to a prothrombotic and proinflammatory state. The main risk factors for metabolic syndrome include obesity, mainly abdominal obesity and insulin resistance [103], as well as aging, physical inactivity and diet rich with saturated fat and cholesterol [103].

Recent studies have tested the hypothesis of a positive association between *H. pylori* and metabolic syndrome [22, 104–106]. While the underlying mechanisms remain to be determined, the inflammatory response to infection and secretion of cytokines such as tumor necrosis factor alpha (TNF- $\alpha$ ) and interleukin-1 (IL-1), IL-6 and IL-8 likely play a role in the postulated association. Additionally, *H. pylori*-induced atrophic gastritis, which develops with aging, reduces the levels of vitamin B12 and folate, which increase homocysteine levels, a known risk factor for insulin resistance [104].

The evidence from epidemiological studies on the association between *H. pylori* infection and metabolic syndrome has been evolving over the past few years.

A recent large cross-sectional study conducted among 3578 persons aged 18–64 years from Taiwan has demonstrated that *H. pylori* infected persons (according to urea breath test [UBT]) had a significantly increased prevalence of metabolic syndrome than uninfected persons; 12.4 vs. 7.4% ( $P < 0.001$ ) in men and 7.4 vs. 2.5% in women ( $P < 0.001$ ) [105]. In this study, metabolic syndrome was defined based on National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Criteria, which were adjusted to the Taiwanese population [105].

The observed positive associations between *H. pylori* infection and metabolic syndrome were attenuated in multivariable analyses, while adjusting for confounders such as age, smoking and alcohol drinking; adjusted odds ratio (OR) 1.91 (95% CI: 1.03–3.53) in women, while in men the association was not statistically significant: adjusted OR: 1.38 (95% CI: 0.97–1.95) [105].

A population-based study conducted among adults aged 25 years or over in Iran also reported a 1.5-fold significantly increased prevalence of metabolic syndrome (according to NCEP-ATP-III criteria) among *H. pylori* (based on serum IgG detection) infected men and women compared with uninfected ones [107]. The same study reported positive associations in relation to exposure to other infectious agents as well such as *Chlamydia pneumoniae*, *Herpes simplex virus 1* (HSV-1) and *Cytomegalovirus* (CMV) [107]. From this study, it is not clear whether the results were adjusted for confounders, and which ones [107].

Gunji et al. [106], in a well-designed study carried out among 5488 Japanese men (mean age  $47 \pm 5$  years) and 1906 women (mean age  $46 \pm 4$  years), demonstrated a significant positive relationship between *H. pylori* seropositivity (according to the presence of IgG antibodies) and metabolic syndrome (based on the Japanese diagnostic criteria); adjusted OR: 1.39 (95% CI: 1.18–1.62)  $P < 0.001$  [106]. This association was independent of known risk factors for metabolic syndrome namely age, sex, diet and smoking [106].

While there is a growing compelling evidence from large epidemiological studies supporting the existence of a positive association between *H. pylori* infection and metabolic syndrome, other studies reported no significant association [108] or reported small magnitude association measures [109]. Therefore, the question of whether *H. pylori* infection is associated with metabolic syndrome, although biologically plausible, remains to be determined, as well as the source of variation among the studies in their findings. Multi-national studies employing similar clinical, epidemiological and diagnostic protocols and methods will be needed to assess true population-to-population variations.

## 6. Conclusions and future directions

Current evidence is conflicting regarding the question of whether *H. pylori* may be associated with an increased risk of DM, metabolic syndrome and poor glycemic control. Although an association between *H. pylori* infection and DM is biologically plausible [110], the nature of such an association is not yet understood. This is due, in part, to important methodological limitations apparent in studies that addressed the relationship between *H. pylori* infection and DM, including inadequate control for socioeconomic status and for known DM risk factors. Moreover, most studies focused on DM, and less on the reversible conditions of IGT, and IFG. Understanding the role in this association of pathogen-related factors, i.e., virulence antigens such as CagA and VacA is still limited. In addition, it is not clear which biological mechanisms may contribute to the postulated excess risk of DM and/or metabolic syndrome in *H. pylori* infected persons compared with uninfected ones. Importantly, it is not yet clear whether *H. pylori* eradication may be beneficial for glycemic control in diabetic patients. Randomized placebo-controlled trials assessing such research questions are lacking.



Addressing these research questions is of great public health and clinical significance given the high prevalence of *H. pylori* infection and significant burden of DM. If *H. pylori* infection is truly involved in the etiology of DM, even to a small magnitude (i.e., small relative risks), the public health impact is expected to be great, given the high prevalence of the infection.

## Author details

Saeda Haj, Michal Raviv and Khitam Muhsen\*

\*Address all correspondence to: kmuhsen@post.tau.ac.il; khitam15@yahoo.com

Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel

## References

- [1] Muhsen K, Jurban M, Goren S, Cohen D. Incidence, age of acquisition and risk factors of Helicobacter pylori infection among Israeli Arab Infants. *J Trop Pediatr* 2012; 58(3): 208–13.
- [2] Rothenbacher D, Inceoglu J, Bode G, Brenner H. Acquisition of Helicobacter pylori infection in a high-risk population occurs within the first 2 years of life. *J Pediatr* 2000; 136(6): 744–8.
- [3] Torres J, Perez-Perez G, Goodman KJ, et al. A comprehensive review of the natural history of Helicobacter pylori infection in children. *Arch Med Res* 2000; 31(5): 431–69.
- [4] Muhsen K, Athamna A, Athamna M, Spungin-Bialik A, Cohen D. Prevalence and risk factors of Helicobacter pylori infection among healthy 3- to 5-year-old Israeli Arab children. *Epidemiol Infect* 2006; 134(5): 990–6.
- [5] Muhsen K, Athamna A, Bialik A, Alpert G, Cohen D. Presence of Helicobacter pylori in a sibling is associated with a long-term increased risk of H. pylori infection in Israeli Arab children. *Helicobacter* 2010; 15(2): 108–13.
- [6] Weyermann M, Adler G, Brenner H, Rothenbacher D. The mother as source of Helicobacter pylori infection. *Epidemiology* 2006; 17(3): 332–4.
- [7] Suerbaum S, Michetti P. Helicobacter pylori infection. *N Engl J Med* 2002; 347(15): 1175–86.
- [8] Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012; 61(5): 646–64.

- [9] Atherton JC. The pathogenesis of *Helicobacter pylori*-induced gastro-duodenal diseases. *Ann Rev Pathol* 2006; 1: 63–96.
- [10] Atherton JC, Blaser MJ. Coadaptation of *Helicobacter pylori* and humans: ancient history, modern implications. *J Clin Invest* 2009; 119(9): 2475–87.
- [11] Kuipers EJ, Uytterlinde AM, Pena AS, et al. Long-term sequelae of *Helicobacter pylori* gastritis. *Lancet* 1995; 345(8964): 1525–8.
- [12] Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of *Helicobacter pylori* gastritis. Results of a 32-year follow-up study. *Scand J Gastroenterol* 1996; 31(6): 546–50.
- [13] Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. *Cancer Res* 1990; 50(15): 4737–40.
- [14] Ganga-Zandzou PS, Michaud L, Vincent P, et al. Natural outcome of *Helicobacter pylori* infection in asymptomatic children: a two-year follow-up study. *Pediatrics* 1999; 104(2 Pt 1): 216–21.
- [15] Monack DM, Mueller A, Falkow S. Persistent bacterial infections: the interface of the pathogen and the host immune system. *Na Rev Microbiol* 2004; 2(9): 747–65.
- [16] Nomura AM, Kolonel LN, Miki K, et al. *Helicobacter pylori*, pepsinogen, and gastric adenocarcinoma in Hawaii. *J Infect Dis* 2005; 191(12): 2075–81.
- [17] Peek RM, Jr., Blaser MJ. Pathophysiology of *Helicobacter pylori*-induced gastritis and peptic ulcer disease. *Am J Med* 1997; 102(2): 200–7.
- [18] Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. *Helicobacter pylori* infection and gastric cancer risk: evaluation of 15 *H. pylori* proteins determined by novel multiplex serology. *Cancer Res* 2009; 69(15): 6164–70.
- [19] Gao L, Weck MN, Michel A, Pawlita M, Brenner H. Association between chronic atrophic gastritis and serum antibodies to 15 *Helicobacter pylori* proteins measured by multiplex serology. *Cancer Res* 2009; 69(7): 2973–80.
- [20] Epplein M, Zheng W, Xiang YB, et al. Prospective study of *Helicobacter pylori* biomarkers for gastric cancer risk among Chinese men. *Cancer Epidemiol Biomarkers* 2012; 21(12): 2185–92.
- [21] Epplein M, Zheng W, Li HL, et al. Diet, *Helicobacter pylori* strain-specific infection, and gastric cancer risk among Chinese men. *Nutr Cancer* 2014; 66(4): 550–7.
- [22] Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and *Helicobacter pylori*. *Helicobacter* 2015; 20(Suppl 1): 40–6.
- [23] Lai CY, Yang TY, Lin CL, Kao CH. *Helicobacter pylori* infection and the risk of acute coronary syndrome: a nationwide retrospective cohort study. *Eur J Clin Microbiol Infect Dis* 2015; 34(1): 69–74.

- [24] Liu J, Wang F, Shi SL. Helicobacter pylori infection increase the risk of myocardial infarction: a meta-analysis of 26 studies involving more than 20,000 participants. *Helicobacter* 2015; 20(3): 176–83.
- [25] Shmueli H, Wattad M, Solodky A, Yahav J, Samra Z, Zafrir N. Association of Helicobacter pylori with coronary artery disease and myocardial infarction assessed by myocardial perfusion imaging. *Isr Med Assoc J* 2014; 16(6): 341–6.
- [26] Kountouras J, Tsolaki M, Boziki M, et al. Association between Helicobacter pylori infection and mild cognitive impairment. *Eur J Neurol* 2007; 14(9): 976–82.
- [27] Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. *Neurology* 2006; 66(6): 938–40.
- [28] Huang WS, Yang TY, Shen WC, Lin CL, Lin MC, Kao CH. Association between Helicobacter pylori infection and dementia. *J Clin Neurosci* 2014; 21(8): 1355–8.
- [29] Wang F, Liu J, Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. *Scand J Infect Dis* 2013; 45(12): 930–8.
- [30] Jeon CY, Haan MN, Cheng C, et al. Helicobacter pylori infection is associated with an increased rate of diabetes. *Diabetes Care* 2012; 35(3): 520–5.
- [31] Cover TL, Blaser MJ. Helicobacter pylori in health and disease. *Gastroenterology* 2009; 136(6): 1863–73.
- [32] Calam J, Gibbons A, Healey ZV, Bliss P, Arebi N. How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology. *Gastroenterology* 1997; 113(6): S43–9.
- [33] Sipponen P, Kekki M, Seppala K, Siurala M. The relationships between chronic gastritis and gastric acid secretion. *Aliment Pharmacol Ther* 1996; 10(Suppl 1): 103–18.
- [34] Zhang ZW, Patchett SE, Perrett D, Katelaris PH, Domizio P, Farthing MJG. The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. *Gut* 1998; 43(3): 322–6.
- [35] Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. *Gastroenterology* 1971; 61(2): 185–8.
- [36] Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. *Gastroenterology* 1973; 65(1): 36–42.
- [37] Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. *J Dig Dis* 2007; 8(1): 8–14.
- [38] Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. *Clin Gastroenterol Hepatol* 2006; 4(3): 306–14.

- [39] Song HJ, Jang SJ, Yun SC, et al. Low levels of Pepsinogen I and Pepsinogen I/II ratio are valuable serologic markers for predicting extensive gastric corpus atrophy in patients undergoing endoscopic mucosectomy. *Gut Liver* 2010; 4(4): 475–80.
- [40] He CY, Sun LP, Gong YH, Xu Q, Dong NN, Yuan Y. Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs. *J Gastroenterol Hepatol* 2011; 26(6): 1039–46.
- [41] Roper J, Francois F, Shue PL, et al. Leptin and ghrelin in relation to *Helicobacter pylori* status in adult males. *J Clin Endocrinol Metab* 2008; 93(6): 2350–7.
- [42] Nweneka CV, Prentice AM. *Helicobacter pylori* infection and circulating ghrelin levels—a systematic review. *BMC Gastroenterol* 2011; 11: 7.
- [43] Breidert M, Miehle S, Glasow A, et al. Leptin and its receptor in normal human gastric mucosa and in *Helicobacter pylori*-associated gastritis. *Scand J Gastroenterol* 1999; 34(10): 954–61.
- [44] Isomoto H, Ueno H, Nishi Y, Wen CY, Nakazato M, Kohno S. Impact of *Helicobacter pylori* infection on ghrelin and various neuroendocrine hormones in plasma. *World J Gastroenterol* 2005; 11(11): 1644–8.
- [45] Francois F, Roper J, Joseph N, et al. The effect of *H. pylori* eradication on meal-associated changes in plasma ghrelin and leptin. *BMC Gastroenterol* 2011; 11: 37.
- [46] Chuang CH, Sheu BS, Yang HB, et al. Gender difference of circulating ghrelin and leptin concentrations in chronic *Helicobacter pylori* infection. *Helicobacter* 2009; 14(1): 54–60.
- [47] Azuma T, Suto H, Ito Y, et al. Gastric leptin and *Helicobacter pylori* infection. *Gut* 2001; 49(3): 324–9.
- [48] Cummings DE, Overduin J. Gastrointestinal regulation of food intake. *J Clin Invest* 2007; 117(1): 13–23.
- [49] Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999; 402(6762): 656–60.
- [50] Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. *Nature* 2001; 409(6817): 194–8.
- [51] Bado A, Lévassieur S, Attoub S, et al. The stomach is a source of leptin. *Nature* 1998; 394(6695): 790–3.
- [52] Jun DW, Lee OY, Lee YY, Choi HS, Kim TH, Yoon BC. Correlation between gastrointestinal symptoms and gastric leptin and ghrelin expression in patients with gastritis. *Digest Dis Sci* 2007; 52(10): 2866–72.

- [53] Nishi Y, Isomoto H, Uotani S, et al. Enhanced production of leptin in gastric fundic mucosa with Helicobacter pylori infection. *World J Gastroenterol* 2005; 11(5): 695–9.
- [54] Jang EJ, Park SW, Park JS, et al. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. *J Gastroenterol Hepatol* 2008; 23(Suppl 2): S278–85.
- [55] Powers AC. Harrison's Principles of Internal Medicine, 18e. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Chapter 344, Diabetes Mellitus. 18e ed: The McGraw-Hill Companies, Inc.; 2013.
- [56] van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. *Eur J Cardiovasc Prev Rehabil* 2010; 17(Suppl 1): S3–8.
- [57] Monesi L, Baviera M, Marzona I, et al. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. *Diabet Med* 2012; 29(3): 385–92.
- [58] Astrup A. Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. *Public Health Nutr* 2001; 4(2B): 499–515.
- [59] Joshi SR, Saboo B, Vadivale M, et al. Prevalence of Diagnosed and Undiagnosed Diabetes and Hypertension in India-Results from the Screening India's Twin Epidemic (SITE) Study. *Diabetes Technol The* 2012; 14(1): 8–15.
- [60] Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. *Ann N Y Acad Sci* 2013; 1281: 51–63.
- [61] Steyn NP, Mann J, Bennett PH, et al. Diet, nutrition and the prevention of type 2 diabetes. *Public Health Nutr* 2004; 7(1A): 147–65.
- [62] Hu FB, Li TY, Colditz GA, Willett WC, Manson JE. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. *JAMA* 2003; 289(14): 1785–91.
- [63] Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N Engl J Med* 2001; 345(11): 790–7.
- [64] Medalie JH, Papier CM, Goldbourt U, Herman JB. Major factors in the development of diabetes mellitus in 10,000 men. *Arch Intern Med* 1975; 135(6): 811–7.
- [65] Beaty TH, Neel JV, Fajans SS. Identifying risk factors for diabetes in first degree relatives of non-insulin dependent diabetic patients. *Am J Epidemiol* 1982; 115(3): 380–97.
- [66] Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. *Diabetologia* 1984; 26(1): 44–9.

- [67] van Dam RM. The epidemiology of lifestyle and risk for type 2 diabetes. *Eur J Epidemiol* 2003; 18(12): 1115–25.
- [68] Espelt A, Arriola L, Borrell C, Larranaga I, Sandin M, Escolar-Pujolar A. Socioeconomic position and type 2 diabetes mellitus in Europe 1999–2009: a panorama of inequalities. *Current Diabetes Rev* 2011; 7(3): 148–58.
- [69] Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. *Int J Epidemiol* 2011; 40(3): 804–18.
- [70] Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. *Diabetologia* 1991; 34(12): 891–8.
- [71] Ryan DH, Diabetes Prevention Program Research G. Diet and exercise in the prevention of diabetes. *Int J Clin Pract Supplement* 2003; (134): 28–35.
- [72] Walker KZ, O'Dea K, Gomez M, Girgis S, Colagiuri R. Diet and exercise in the prevention of diabetes. *J Hum Nutr Diet* 2010; 23(4): 344–52.
- [73] Sukala WR, Page R, Cheema BS. Exercise training in high-risk ethnic populations with type 2 diabetes: a systematic review of clinical trials. *Diabetes Res Clin Pr* 2012; 97(2): 206–16.
- [74] Weigt J, Malfertheiner P. Influence of *Helicobacter pylori* on gastric regulation of food intake. *Curr Opin Clin Nutr Metab Care* 2009; 12(5): 522–5.
- [75] Isomoto H, Ueno H, Saenko VA, et al. Impact of *Helicobacter pylori* infection on gastric and plasma ghrelin dynamics in humans. *Am J Gastroenterol* 2005; 100(8): 1711–20.
- [76] Liew PL, Lee WJ, Lee YC, Chen WY. Gastric ghrelin expression associated with *Helicobacter pylori* infection and chronic gastritis in obese patients. *Obes Surg* 2006; 16(5): 612–9.
- [77] Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. *Diabetes* 2001; 50(8): 1714–9.
- [78] Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. *Diabetes* 2001; 50(2): 227–32.
- [79] Wolf G. Leptin: the weight-reducing plasma protein encoded by the obese gene. *Nutr Rev* 1996; 54(3): 91–3.
- [80] Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science* 1995; 269(5223): 543–6.

- [81] Chen Y, Blaser MJ. Association between gastric Helicobacter pylori colonization and glycosylated hemoglobin levels. *J Infect Dis* 2012; 205(8): 1195–202.
- [82] Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. *Helicobacter* 2011; 16(2): 79–88.
- [83] Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. *Turk J Gastroenterol* 2007; 18(4): 225–9.
- [84] Zhou X, Zhang C, Wu J, Zhang G. Association between Helicobacter pylori infection and diabetes mellitus: a meta-analysis of observational studies. *Diabetes Res Clin Pract* 2013; 99(2): 200–8.
- [85] Wang F, Liu J, Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy: a meta-analysis of 39 studies involving more than 20,000 participants. *Scand J Infect Dis* 2013; 45(12): 930–8.
- [86] Hsieh MC, Wang SSW, Hsieh YT, Kuo FC, Soon MS, Wu DC. Helicobacter pylori infection associated with high HbA1c and type 2 diabetes. *Eur J Clin Invest* 2013; 43(9): 949–56.
- [87] Dore MP, Bilotta M, Malaty HM, et al. Diabetes mellitus and Helicobacter pylori infection. *Nutrition* 2000; 16(6): 407–10.
- [88] Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and type 2 diabetes: the MultiEthnic Study of Atherosclerosis. *Diabet Med* 2009; 26(2): 149–52.
- [89] Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. *Am J Gastroenterol* 2001; 96(4): 1039–46.
- [90] Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. *Dig Dis Sci* 2008; 53(10): 2646–9.
- [91] Longo-Mbenza B, Nsenga JN, Mokondjimobe E, et al. Helicobacter pylori infection is identified as a cardiovascular risk factor in Central Africans. *VascHealth Risk manag* 2012; 6: 455–61.
- [92] Cenerelli S, Bonazzi P, Galeazzi R, et al. Helicobacter pylori masks differences in homocysteine plasma levels between controls and type 2 diabetic patients. *Eur J Clin Invest* 2002; 32(3): 158–62.
- [93] Horikawa C, Kodama S, Fujihara K, et al. Association of Helicobacter pylori infection with glycemic control in patients with diabetes: a meta-analysis. *J Diabetes Res* 2014.

- [94] Dai YN, Yu WL, Zhu HT, Ding JX, Yu CH, Li YM. Is *Helicobacter pylori* infection associated with glycemic control in diabetics? *World J Gastroenterol* 2015; 21(17): 5407–16.
- [95] Zojaji H, Ataei E, Sherafat SJ, Ghobakhlou M, Fatemi SR. The effect of the treatment of *Helicobacter pylori* infection on the glycemic control in type 2 diabetes mellitus. *Gastroenterol Hepatol* 2013; 6(1): 36–40.
- [96] Wada Y, Hamamoto Y, Kawasaki Y, et al. The eradication of *Helicobacter pylori* does not affect glycemic control in Japanese subjects with type 2 diabetes. *Jap Clin Med* 2013; 4: 41–3.
- [97] Vafaeimanesh J, Rajabzadeh R, Ahmadi A, et al. Effect of *Helicobacter pylori* eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens. *Arab J Gastroenterol* 2013; 14(2): 55–8.
- [98] Akanuma M, Yanai A, Sakamoto K, et al. Influence of *Helicobacter pylori* eradication on the management of type 2 diabetes. *Hepato-Gastroenterology* 2012; 59(114): 641–5.
- [99] Candelli M, Rigante D, Marietti G, et al. *Helicobacter pylori* eradication rate and glycemic control in young patients with type 1 diabetes. *J Pediatr Gastroenterol Nutr* 2004; 38(4): 422–5.
- [100] Begue RE, Gomez R, Compton T, Vargas A. Effect of *Helicobacter pylori* eradication in the glycemia of children with type 1 diabetes: a preliminary study. *South Med J* 2002; 95(8): 842–5.
- [101] de Luis DA, Cordero JM, Caballero C, et al. Effect of the treatment of *Helicobacter pylori* infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus. *DiabResClin Pract* 2001; 52(1): 1–9.
- [102] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Curr Opin Cardiol* 2006; 21(1): 1–6.
- [103] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005; 112(17): 2735–52.
- [104] Polyzos SA, Kountouras J. Novel advances in the association between *Helicobacter pylori* infection, metabolic syndrome, and related morbidity. *Helicobacter* 2015; 20(6): 405–9.
- [105] Chen TP, Hung HF, Chen MK, et al. *Helicobacter pylori* infection is positively associated with metabolic syndrome in Taiwanese adults: a cross-sectional study. *Helicobacter* 2015; 20(3): 184–91.



- [106] Gunji T, Matsuhashi N, Sato H, et al. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. *Am J Gastroenterol* 2008; 103(12): 3005–10.
- [107] Nabipour I, Vahdat K, Jafari SM, Pazoki R, Sanjdideh Z. The association of metabolic syndrome and Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, and herpes simplex virus type 1: The Persian Gulf Healthy Heart Study. *Cardiovasc Diabetol* 2006; 5.
- [108] Naja F, Nasreddine L, Hwalla N, et al. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. *Helicobacter* 2012; 17(6): 444–51.
- [109] Shin DW, Kwon HT, Kang JM, et al. Association between metabolic syndrome and Helicobacter pylori infection diagnosed by histologic status and serological status. *J Clin Gastroenterol* 2012; 46(10): 840–5.
- [110] He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact? *World J Gastroenterol* 2014; 20(16): 4607–17.
- [111] El-Eshmawy MM, El-Hawary AK, Abdel Gawad SS, El-Baiomy AA. Helicobacter pylori infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis. *Diabetol Metab Syndr* 2011; 3(1).
- [112] Colombo C TP, Meloni GF, Marinaro AM, Ogana A, Meloni T. Seroprevalence of Helicobacter pylori in children with type 1 diabetes mellitus in Sardinia. *Diabetes Nutr Metab* 2002; 15: 91–5.